Healthcare advocates call for universal coverage, acknowledge challenges

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Washington, DC-The idea of universal healthcare coverage was a crowd pleaser at the 2009 Annual Advocacy Training Conference of the National Breast Cancer Coalition, but expert panelists agreed that making that dream into a reality will take time and perseverance.

Washington, DC-The idea of universal healthcare coverage was a crowd pleaser at the 2009 Annual Advocacy Training Conference of the National Breast Cancer Coalition, but expert panelists agreed that making that dream into a reality will take time and perseverance.

At an NBCC plenary session, participants compared the attempted reform of the health system during the administration of President Bill Clinton to the current situation.

“We’re in the same position today that we were then, but some things are different now. President Obama is much more popular than Mr. Clinton was, and major stakeholders are in a more powerful position than they were 15 years ago,” said session moderator Joanne Howes, a women’s health policy consultant and a partner with DDB Issues & Advocacy.

Women are some of those major stakeholders now, said Cindy Pearson, executive director of the National Women’s Health Network. Women have been responsible for most of the public health gains in this country, such as the promotion of breast cancer screening and clinical trial recruitment.

Obviously, more public participation is needed. Carmella Bocchino, executive vice president of clinical affairs and strategic planning at America’s Health Insurance Plans, said that consumers must be part of the debate on healthcare reform. “President Barack Obama has laid out an eight-pillar plan for change and he knows that tackling cost containment has to be the first order of business,” she said.

However, Judith Feder, PhD, a professor of public policy at the Georgetown Public Policy Institute in Washington, DC, warned that healthcare reform cannot be so drastic that it frightens consumers. “To truly change the system, emphasis should be placed on prevention, on rewarding good care, and providing only necessary care. Consumers understand these things but are reluctant to practice them,” she said.

Jeffrey Levi, executive director of the Trust for America’s Health, said that he believes the most important elements of President Obama’s eight pillars are health IT, comparative effectiveness of health research, and community level prevention. “However, if bills to achieve these goals are perceived as too expensive, they won’t be passed,” he cautioned.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content